| ID | Sequence | Length | GC content |
|---|---|---|---|
| CUACUCAGCCCCAGCGGAGGUGAAGGACGUCCUUCCCCAGGAGCCGACU… | 1166 nt | 0.6904 | |
| CUACUCAGCCCCAGCGGAGGUGAAGGACGUCCUUCCCCAGGAGCCGGUG… | 1248 nt | 0.6891 | |
| AGAGACGACCCGACCCGCUAGAAGACUGGCCAAUCACAGGCAGGAAGAU… | 1144 nt | 0.6897 | |
| GGAUGGGGAGAUAAGAGAAGACCAGGAGGGAGUUAAAUAGGGAAUGGGU… | 1244 nt | 0.6736 | |
| CUACUCAGCCCCAGCGGAGGUGAAGGACGUCCUUCCCCAGGAGCCGUUU… | 1181 nt | 0.6884 |
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016]
A study in mice demonstrated that the APOE was downregulated in monocytes from heart and lung tissues of septic mice compared to sham mice [Li et al. DOI:10.1007/s00011-025-02068-7]. A study in humans demonstrated that the APOE gene was upregulated in subcutaneous adipose tissue during short-term weight loss, with its expression pattern showing a reciprocal relationship to acquired obesity in BMI-discordant monozygotic twin pairs [Bollepalli et al. DOI:10.1038/ijo.2017.245].